Work

Supplementary Figures and Tables from Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Year: 2023

Type: supplementary-materials

Abstract: Fig. S1A: Individual HPV16 kinetics among the 1 dose group. Fig. S1B: Individual HPV18 kinetics among the 1 dose group. Fig. S1C: Individual HPV16 kinetics among the 2-dose(0/1) group. Fig. S1D: Individual HPV18 kinetics among the 2-dose(0/1) group. Fig. S1E: Individual HPV16 kinetics among the 2-dose(0/6) group. Fig. S1F: Individual HPV18 kinetics among the 2-dose(0/6) group. Fig. S1G: Individual kinetics HPV16 among the 3-dose group. Fig. S1H: Individual kinetics HPV18 among the 3-dose group. Fig. S2A: Relation of HPV16 antibody levels at 12 months and 48 months among women who received one vaccine dose. Fig. S2B: Relation of HPV18 antibody levels at 12 months and 48 months among women who received one vaccine dose. Table S1: Comparison of selected enrollment characteristics by vaccine dose group.

DOI: 10.1158/1940-6207.22525667.v1

Authors: Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim, Ligia A. Pinto

Language: English

Topic: Cervical Cancer and HPV Research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362625562

Cites:

Cited by:

Related to: 10